Pasar al contenido principal

DESCUBRIENDO EL INTERACTOMA HUMANO EN EL ICTUS. IDENTIFICACION DE MEDIADORES DE DAÑO O PROTECCION EN LA ISQUEMIA CEREBRAL

PI18/00255

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
Centro realización INSTITUTO RAMON Y CAJAL DE INVESTIGACION SANITARIA (IRYCIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The transition to motherhood, linking hormones, brain and behaviour

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Pretus, Clara|||0000-0003-2172-1184
  • Paternina-Die, María|||0000-0002-5100-4955
  • Soler Campillo, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Leuner, Benedetta|||0000-0002-8919-6892
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
We are witnessing a stark increase in scientific interest in the neurobiological processes associated with pregnancy and maternity. Convergent evidence suggests that around the time of labour, first-time mothers experience a specific pattern of neuroanatomical changes that are associated with maternal behaviour. Here we provide an overview of the human neurobiological adaptations of motherhood, focusing on the interplay between pregnancy-related steroid and peptide hormones, and neuroplasticity in the brain. We discuss which brain plasticity mechanisms might underlie the structural changes detected by MRI, which hormonal systems are likely to contribute to such neuroanatomical changes and how these brain mechanisms may be linked to maternal behaviour. This Review offers an overarching framework that can serve as a roadmap for future investigations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Aliena-Valero, Alicia
  • Torregrosa, Germán
  • Chioua, Mourad
  • Fernández-Serra, Rocío
  • González-Nieto, Daniel
  • Ouahid, Youness
  • Salom, Juan B.
  • Masjuán, Jaime
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these results pointing to QN23 as an interesting and promising preclinical candidate for the treatment of AIS., This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER) through grants PI18/00255, RD16/0019/0006, and RD21/0006/0019 to J.M. and A.A., and RD16/0019/0008 and RD21/0006/0014 to J.B.S.; the MINECO grant SAF2015-65586-R to J.M.-C.; and the Comunidad de Madrid Neurocentro project B2017/BMD-3760 to D.G.-N.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of a CholesteroNitrone (ISQ-201), a Novel Drug Candidate for the Treatment of Ischemic Stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Ayuso, Maria I.
  • Gonzalo Gobernado, Rafael|||0000-0002-6357-105X
  • Chioua, Mourad
  • Montoya, Juan J.
  • Montaner, Joan|||0000-0003-4845-2279
  • Fernández, Israel|||0000-0002-0186-9774
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones have a well-recognized capacity as spin-traps and are considered powerful free radical scavengers, which are two important issues in hypoxia-induced oxidative stress and cell death in brain ischemia. Consequently, nitrones have been proposed as therapeutic agents in acute ischemic stroke (AIS). In this paper, we update the biological and pharmacological characterization of ISQ-201, a previously identified cholesteronitrone hybrid with antioxidant and neuroprotective activity. This study characterizes ISQ-201 as a neuroprotective agent against the hypoxia-induced ischemic injury. Transitory four-vessel occlusion and middle cerebral artery occlusion (tMCAO) were used to induce cerebral ischemia. Functional outcomes were determined using neurofunctional tests. Infarct area, neuronal death, and apoptosis induction were evaluated. In addition, ISQ-201 reactivity towards free radicals was studied in a theoretical model. ISQ-201 significantly decreased the ischemia-induced neuronal death and apoptosis, in a dose-dependent manner, showing its therapeutic effect when administered up until 6 h after post-ischemic reperfusion onset, effects that remained after 3 months from the ischemic episode. Furthermore, ISQ-201 significantly reduced infarct volume, leading to recovery of the motor function in the tMCAO model. Finally, the theoretical study confirmed the reactivity of ISQ-201 towards hydroxyl radicals. The results reported here prompted us to suggest ISQ-201 as a promising candidate for the treatment of AIS